EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples